Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Kiyoi

Showing results (181-190 of 238) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphomaKazuhito Yamamoto, Atae Utsunomiya, Kensei Tobinai, et al.
Blood Advances|June 18, 2026
Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CMLNaoto Takahashi, Yosuke Minami, Yuki Fujioka, et al.
Stem Cell Reports|May 29, 2018
Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell ResponseNorihiro Ueda, Yasushi Uemura, Rong Zhang, et al.
International Journal of Hematology|November 24, 2020
Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study GroupTakeshi Saito, Yoshihiro Hatta, Fumihiko Hayakawa, et al.
Scientific Reports|March 1, 2016
Identification of Meflin as a Potential Marker for Mesenchymal Stromal CellsKeiko Maeda, Atsushi Enomoto, Akitoshi Hara, et al.
Blood Advances|June 11, 2026
Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIsTakaaki Ono, Takashi Okada, Naoto Takahashi, et al.
Blood|July 5, 2005
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemiaTatsuya Suzuki, Hitoshi Kiyoi, Kazutaka Ozeki, et al.
Transplantation and Cellular Therapy|December 7, 2021
Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete RemissionShinichi Kako, Fumihiko Hayakawa, Koichi Miyamura, et al.
Cancer Science|May 12, 2020
Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT studyNaomi Kawashima, Yuichi Ishikawa, Yoshiko Atsuta, et al.
International Journal of Hematology|August 27, 2025
Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial dataSatoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, et al.
Pageof 24

Showing results (181-190 of 238) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphomaKazuhito Yamamoto, Atae Utsunomiya, Kensei Tobinai, et al.
Blood Advances|June 18, 2026
Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CMLNaoto Takahashi, Yosuke Minami, Yuki Fujioka, et al.
Stem Cell Reports|May 29, 2018
Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell ResponseNorihiro Ueda, Yasushi Uemura, Rong Zhang, et al.
International Journal of Hematology|November 24, 2020
Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study GroupTakeshi Saito, Yoshihiro Hatta, Fumihiko Hayakawa, et al.
Scientific Reports|March 1, 2016
Identification of Meflin as a Potential Marker for Mesenchymal Stromal CellsKeiko Maeda, Atsushi Enomoto, Akitoshi Hara, et al.
Blood Advances|June 11, 2026
Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIsTakaaki Ono, Takashi Okada, Naoto Takahashi, et al.
Blood|July 5, 2005
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemiaTatsuya Suzuki, Hitoshi Kiyoi, Kazutaka Ozeki, et al.
Transplantation and Cellular Therapy|December 7, 2021
Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete RemissionShinichi Kako, Fumihiko Hayakawa, Koichi Miyamura, et al.
Cancer Science|May 12, 2020
Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT studyNaomi Kawashima, Yuichi Ishikawa, Yoshiko Atsuta, et al.
International Journal of Hematology|August 27, 2025
Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial dataSatoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, et al.
Pageof 24